Pathogenetic Mechanism of Type 2 Diabetes Mellitus and its Clinical Implications

Abstract

Oxidative stress is an important pathogenetic mechanism for the development of type 2 diabetes mellitus (T2DM) and its complications. Oxidative stress is an imbalance of the generation of free radicals (reactive oxygen species [ROS] and reactive nitrogen species [RNS]) and their neutralization by the antioxidant mechanisms. Increased levels of ROS and RNS lead to damage of lipids, proteins, and DNA, ultimately causing the destruction of the islet cells of pancreas through apoptosis. Another important factor in the development of diabetes mellitus and metabolic syndrome is inflammation. We studied oxidative stress in type 2 diabetic patients, patients with obesity, metabolic syndrome, and T2DM with iron-deficiency anemia. The elevation of oxidative stress in these conditions along with the increase in inflammation suggests that both oxidative stress and inflammation may heighten the risk for the development of T2DM and its complications.

Keywords

oxidative stress - diabetes mellitus - obesity - anemia

• References

• 1 Diabetes Atlas. 8th ed.. Global Fact Sheet. Brussels, Belgium: International Diabetes Federation; 2017
• 2 Kempegowda P, Marcus SR, Solanki P, Reddy RS, Nandini DR, Dharmalingam M. Prevalence of the metabolic syndrome in rural India—a disparity in definitions. Int J Diabetes Dev Countries 2011; 31 (04) 188-193
• 3 Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88 (04) 947-999
• 4 Vasudevan DM, Sreekumari S. Textbook of Biochemistry. 3rd ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd 2001: 338-339
• 5 Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009; 84 (21) (22) 705-712
• 6 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54 (06) 1615-1625
• 7 Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappa B activation in insulin-producing cells. Diabetes 2003; 52 (01) 93-101
• 8 Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111 (11) 1448-1454
• 9 Kalaivanam KN, Dharmalingam M, Marcus SR. Oxidative protein and lipid damage in type 2 diabetes mellitus. Paper presented at: International Conference on “Antioxidants and Free Radicals in Health-Nutrition & Radio-Protectors” 4th Annual Conference of Society for Free Radical Research in India. 2005. Bangalore, India
• 10 Kalaivanam KN, Dharmalingam M, Marcus SR. Lipid peroxidation in type 2 diabetes mellitus. Int J Diabetes Dev Countries 2006; 26: 30-32
• 11 Dharmalingam M, Dev N, Marcus SR. High-sensitivity C-reactive protein levels in obese women. Paper presented at: 7th International Diabetes Federation Western Pacific Region Congress. 2008. Wellington, New Zealand
• 12 Veigas N, Dharmalingam M, Marcus SR. Oxidative stress in obesity and metabolic syndrome in Asian Indians. J Med Biochem 2011; 30 (02) 115-120
• 13 Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51 (08) 2348-2354
• 14 Ganesh S, Dharmalingam M, Marcus SR. Oxidative stress in type 2 diabetes with iron deficiency in Asian Indians. J Med Biochem 2012; 31 (02) 115-120
• 15 Marcus SR, Dharmalingam M. Iron, oxidative stress and Diabetes. In: Preedy VR. ed. Diabetes: Oxidative Stress and Dietary Antioxidants. Oxford, United Kingdom: Elsevier; 2014: 51-64
• 16 Griesmacher A, Kindhauser M, Andert SE. et al. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 1995; 98 (05) 469-475
• 17 Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction?. Diabetes 2003; 52 (01) 1-8
• 18 Ma X, Chen Z, Wang L. et al. The pathogenesis of diabetes mellitus by oxidative stress and inflammation: its inhibition by berberine. Front Pharmacol 2018; 9: 782
• 19 Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004; 21 (03) 203-207
• 20 Mahmoud F, Al-Ozairi E. Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes. Dis Markers 2013; 35 (04) 235-241
• 21 Donath MY. Targeting inflammation in the treatment of type 2 diabetes. Diabetes Obes Metab 2013; 15 (Suppl. 03) 193-196